Share this article
Share this article POTENTIAL TREATMENT OF SEVERAL SOLID TUMOR CANCERS INCLUDING: NON-SMALL CELL LUNG CANCER, SQUAMOUS CELL CARNINOMA, BREAST CANCER, RENAL CANCER, PANCREATIC CANCER, OVARIAN CANCER, LIVER CANCER, COLORECTAL CANCER BEVERLY HILLS, Calif., Aug. 3, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on developing target-directed, tri-specific Natural Killer (NK) cell engager therapies (TriKE™) incorporating interleukin 15 (IL-15) for the treatment of cancer, announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
GTB-5550 TriKE™ was evaluated in several preclinical models overexpressing B7H3, and was found to be effective at promoting NK cell killing of multiple cancer cell types. B7H3 is over-expressed on several cancer types including non-small cell lung cancer, squamous cell carc
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Operator
Good afternoon, ladies and gentlemen, and welcome to the Acceleron First Quarter 2021 Earnings Conference Call. [Operator Instructions]
I would now like to hand the call over to Ms. Jamie Bernard, Associate Director of Investor Relations at Acceleron. Please go ahead.
Jamie A. Bernard
Associate Director of Investor Relations
Thanks, and welcome, everyone, to our first quarter 2021 earnings call. The press release reporting our financial results in addition to the presentation for today s webcast are available on the Investors & Media page of our corporate website at www.acceleronpharma.com. Joining me on the call this afternoon are Habib Dable, our Chief Executive Officer; Kevin McLaughlin, our Chief Financial Officer; Dr. Jay Backstrom, our Head of Research and Development; Sujay Kango, our Chief Commercial Officer; and Todd James, our Senior Vice President of Corporate Affairs and Investor Relations. As a reminder, we will be making forward-looking statements regar